We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+9.96%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.79B
AUM Growth
-$56M
Cap. Flow
-$584M
Cap. Flow %
-20.93%
Top 10 Hldgs %
31.86%
Holding
129
New
19
Increased
19
Reduced
27
Closed
26

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$67.9M
2
XENT
Intersect ENT, Inc
XENT
+$33.9M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$32.9M
4
NVRO
NEVRO CORP.
NVRO
+$32.8M
5
ACHC icon
Acadia Healthcare
ACHC
+$27.2M

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$130M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$80M
3
AET
Aetna Inc
AET
+$42M
4
CVS icon
CVS Health
CVS
+$39.3M
5
WBA
Walgreens Boots Alliance
WBA
+$31.9M

Sector Composition

Rank Sector Weight
1 Healthcare 68.65%
2 Financials 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$129M 4.64%
6,609,894
– –
QTTB icon
2
Q32 Bio
QTTB
$255M
$119M 4.28%
290,391
– –
AERI
3
DELISTED
Aerie Pharmaceuticals
AERI
$94.8M 3.4%
1,540,448
+1,056,393
+218% +$67.9M
VTRS icon
4
Viatris
VTRS
$20.1B
$67.4M 2.42%
1,842,111
+100,000
+6% +$3.75M
PTLA
5
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$65.4M 2.34%
2,455,586
+1,008,953
+70% +$32.9M
DBVT
6
DBV Technologies
DBVT
$870M
$65.1M 2.33%
290,000
– –
ANAB icon
7
AnaptysBio
ANAB
$1.72B
$64.6M 2.31%
647,466
+84,477
+15% +$7.01M
XLRN
8
DELISTED
Acceleron Pharma
XLRN
$64M 2.29%
1,117,651
-9,149
-0.8% -$450K
ECYT
9
DELISTED
Endocyte, Inc. Common Stock
ECYT
$62.4M 2.24%
3,514,084
+1,189,785
+51% +$20.4M
XENT
10
DELISTED
Intersect ENT, Inc
XENT
$61.8M 2.21%
2,147,950
+1,127,950
+111% +$33.9M
MYOK
11
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$59.8M 2.14%
917,000
-242,000
-21% -$14.2M
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.36B
$52.7M 1.89%
6,910,789
+847,293
+14% +$5.69M
ACHC icon
13
Acadia Healthcare
ACHC
$3.17B
$50.1M 1.8%
1,424,571
+683,555
+92% +$27.2M
ARGX icon
14
argenx
ARGX
$53.8B
$49.8M 1.78%
656,500
+209,471
+47% +$18.6M
SRPT icon
15
Sarepta Therapeutics
SRPT
$1.82B
$47.8M 1.71%
296,000
– –
BKD icon
16
Brookdale Senior Living
BKD
$3.58B
$46.3M 1.66%
4,707,912
+2,402,139
+104% +$22.1M
ACRS icon
17
Aclaris Therapeutics
ACRS
$793M
$44.9M 1.61%
3,093,416
+347,711
+13% +$5.96M
CVS icon
18
CALL
CVS Health
CVS
$137B
$44.6M 1.6%
566,800
– –
XERS icon
19
Xeris Biopharma Holdings
XERS
$1.52B
$43.9M 1.57%
2,498,666
– –
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$41M 1.47%
525,000
+50,050
+11% +$3.48M
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$39.6M 1.42%
840,911
-459,454
-35% -$25.6M
GKOS icon
22
Glaukos
GKOS
$9.21B
$37M 1.32%
569,356
-184,866
-25% -$9.07M
EDIT icon
23
Editas Medicine
EDIT
$457M
$36.9M 1.32%
1,158,841
– –
CNC icon
24
Centene
CNC
$32.8B
$35.5M 1.27%
490,000
-159,072
-25% -$11M
EHTH icon
25
eHealth
EHTH
$47.3M
$34.7M 1.24%
1,227,061
+122,109
+11% +$3.24M
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2018 Portfolio in Review

As of Q3 2018, Deerfield Management held 129 positions worth $2.79B, down 2% from $2.85B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Deerfield Management withdrew a net $584M in Q3 2018, closing 26 positions and reducing 27 holdings. Its most notable exit was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $130M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 74% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in NEVRO CORP. worth $29.9M.

  • Deerfield Management's largest Q3 2018 buy was NEVRO CORP.: 525,040 shares worth $29.9M.
  • Deerfield Management added most to Aerie Pharmaceuticals in Q3 2018, an estimated $67.9M increase.
  • Deerfield Management's biggest Q3 2018 reduction was Tandem Diabetes Care, cutting an estimated $80M.
  • Deerfield Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q3 2018, selling an estimated $130M.
  • Deerfield Management's ten largest holdings make up 32% of its $2.79B portfolio in Q3 2018.
  • Deerfield Management opened 19 new positions and closed 26 in Q3 2018.
  • Deerfield Management's portfolio value fell 2% quarter-over-quarter to $2.79B.

Based on Deerfield Management's 13F filing for Q3 2018, filed 14 Nov 2018.